articles and announcements

Ovid Therapeutics Collaborates with UCONN Health and Stormy Chamberlain, PhD to Develop Gene Therapy for AS

Ovid Therapeutics
July 27, 2020

Ovid Therapeutics Collaborates with UCONN Health and Stormy Chamberlain, PhD to Develop Gene Therapy for AS

On July 23, 2020, Ovid Therapeutics announced a research collaboration with UCONN Health and Stormy Chamberlain, PhD. This exciting work began as an innovative idea funded by the Angelman Syndrome Foundation. Short hairpin RNA (shRNAs) work like ASOs, but can be delivered using AAV, like gene therapy. One dose would last indefinitely.

Ovid will have access to identified genetic sequences for a potential shRNA-based therapeutic. Ovid plans to validate select sequences and leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance an shRNA-based therapeutic into clinical studies.

Thank you to donors to ASF who helped bring us yet another promising potential therapeutic!

See Ovid’s press release for details.